Biohaven Ltd. (NYSE:BHVN) Receives $63.00 Consensus PT from Brokerages

Biohaven Ltd. (NYSE:BHVN) has received an average recommendation of “Buy” from the fourteen brokerages that are presently covering the company, Marketbeat Ratings reports. Thirteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $63.00.

Several equities analysts recently commented on the stock. Leerink Partners upped their price target on shares of Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, September 23rd. TD Cowen boosted their price objective on shares of Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Sanford C. Bernstein increased their target price on Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 24th. Jefferies Financial Group assumed coverage on Biohaven in a research report on Monday, September 16th. They set a “buy” rating and a $57.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th.

Insider Buying and Selling

In other news, Director John W. Childs acquired 29,000 shares of the business’s stock in a transaction on Monday, December 30th. The shares were purchased at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the acquisition, the director now directly owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. This represents a 1.24 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 16.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Biohaven

Several large investors have recently modified their holdings of BHVN. nVerses Capital LLC bought a new stake in shares of Biohaven in the third quarter worth $50,000. Values First Advisors Inc. bought a new stake in shares of Biohaven in the 3rd quarter worth about $78,000. Redwood Wealth Management Group LLC acquired a new stake in shares of Biohaven in the 2nd quarter valued at about $61,000. US Bancorp DE lifted its position in shares of Biohaven by 57.1% during the third quarter. US Bancorp DE now owns 2,173 shares of the company’s stock worth $109,000 after purchasing an additional 790 shares during the last quarter. Finally, KBC Group NV increased its holdings in Biohaven by 24.5% in the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock valued at $112,000 after buying an additional 443 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Stock Down 0.2 %

BHVN stock opened at $37.28 on Friday. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of -3.99 and a beta of 1.24. Biohaven has a 52-week low of $26.80 and a 52-week high of $62.21. The stock’s fifty day simple moving average is $44.41 and its 200-day simple moving average is $41.98.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). As a group, analysts anticipate that Biohaven will post -8.85 earnings per share for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.